PULMONARY FIBROSIS

Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models

Pauline Désogère,1* Luis F. Tapias,2* Lida P. Hariri,3,4 Nicholas J. Rotile,1 Tyson A. Rietz,1 Clemens K. Probst,3 Francesco Blasi,1† Helen Day,15 Mari Mino-Kenudson,4 Paul Weinreb,5 Shelia M. Violette,5 Bryan C. Fuchs,6 Andrew M. Tager,3 Michael Lanuti,2‡ Peter Caravan1‡

Pulmonary fibrosis is scarring of the lungs that can arise from radiation injury, drug toxicity, environmental or genetic causes, and for unknown reasons [idiopathic pulmonary fibrosis (IPF)]. Overexpression of collagen is a hallmark of organ fibrosis. We describe a peptide-based positron emission tomography (PET) probe (\(^{68}\)Ga-CBP8) that targets collagen type I. We evaluated \(^{68}\)Ga-CBP8 in vivo in the bleomycin-induced mouse model of pulmonary fibrosis. \(^{68}\)Ga-CBP8 showed high specificity for pulmonary fibrosis and high target/background ratios in diseased animals. The lung PET signal and lung \(^{68}\)Ga-CBP8 uptake (quantified ex vivo) correlated linearly (\(r^2 = 0.80\)) with the amount of lung collagen in mice with fibrosis. We further demonstrated that the \(^{68}\)Ga-CBP8 probe could be used to monitor response to treatment in a second mouse model of pulmonary fibrosis associated with vascular leak. Ex vivo analysis of lung tissue from patients with IPF supported the animal findings. These studies indicate that \(^{68}\)Ga-CBP8 is a promising candidate for noninvasive imaging of human pulmonary fibrosis.

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a specific form of progressive, fibrosing interstitial pneumonia of unknown etiology that primarily affects older adults. In most cases, it is a relentlessly progressive disease that results in dyspnea and functional decline until death (1, 2). Currently, there is no treatment able to reverse fibrosis in this disease (3).

Despite efforts to establish precise, universally acknowledged diagnosis criteria for IPF, its ascertainment remains a challenge—although high-resolution computed tomography (HRCT) scanning can aid diagnosis of the disease (4). Patients with suspected IPF that show atypical features on HRCT images usually require a surgical lung biopsy to confirm the diagnosis (5, 6); however, many of these patients have physiological impairments and comorbidities that make biopsy a risky procedure.

These challenges highlight the need for the development and validation of diagnostic and prognostic markers specific to IPF to guide treatment decisions. The ability to recognize fibrosis noninvasively, for example, with innovative molecular imaging techniques, could substantially improve management of patients with fibrotic lung disease. In recent years, collagen degradation markers (7), activated macrophages (8, 9), fibroblasts (10, 11), and integrins \(\alpha_v\beta_6\) (12–15) and \(\alpha_v\beta_1\) (16) have been used as diagnostic and prognostic markers. Pulmonary \(^{18}\)F-fluorodeoxyglucose (FDG) uptake has also been reported to be a predictor of global health score and lung physiology in patients with IPF (17–19). \(^{18}\)F-FDG, however, lacks specificity for IPF.

We set out to develop an approach based on direct molecular imaging of type I collagen as a noninvasive means of detecting, as well as staging, pulmonary fibrosis. Fibrosis, regardless of its cause or location, is characterized by excess deposition of collagens, primarily type I collagen, and other extracellular matrix proteins in the parenchyma (20). Histological proof of fibrosis is predicated on collagen staining. We previously described a 16-amino acid disulfide-bridged cyclic peptide that was identified via phage display and that recognized and bound to type I human collagen. This peptide was functionalized with three gadolinium diethyleneetriamine pentaacetic acid chelates to provide magnetic resonance (MR) signal enhancement, and the resulting probe (EP-3533) showed excellent ability to detect and stage disease in preclinical models of cardiac (21, 22), hepatic (23–25), and pulmonary fibrosis (26).

We have next sought to develop an analogous positron emission tomography (PET) probe. PET is a quantitative modality that provides higher spatial resolution than other nuclear imaging techniques in humans and that could be used to quantify pulmonary fibrosis. PET is an accepted method that is already frequently used for investigating lung pathology. Equally important is the growing installed base of PET-CT and PET-MR systems. In the absence of lung architectural distortion (which may not be present early in fibrotic lung diseases), fibrosis may be indistinguishable by HRCT from other pathological processes that attenuate x-ray signals, such as inflammation. By fusing collagen-specific PET with HRCT, however, we hoped to be able to determine whether specific opacities and patterns identified by HRCT are the result of fibrosing disease (27). In addition, the development of PET molecular imaging probes offers a shorter and more economical path to clinical translation than does that of MR imaging (MRI) probes because the low microgram mass dose required for PET allows for an abbreviated preclinical safety and toxicology package to be submitted to regulators to initiate human studies.

Here, we describe a peptide-based, collagen-targeted PET probe, \(^{68}\)Ga-CBP8, and demonstrate its ability to detect and quantify pulmonary fibrosis in two mouse models of disease, as well as show its...
capacity to monitor therapeutic responses. We also evaluated the capacity of the probe to detect fibrosis in lung tissue samples from IPF patients.

RESULTS

\(^{68}\)Ga-CBP8 is a type I collagen specific PET probe with rapid renal clearance

We synthesized a type I collagen–targeted probe, \(^{68}\)Ga-CBP8, and an inactive negative control probe, \(^{68}\)Ga-CBP12. \(^{68}\)Ga-CBP8 and \(^{68}\)Ga-CBP12 are isomers that differ only in the chirality of the cysteine at the 13th amino acid position from the C terminus (fig. S1). The peptide precursors of both probes were conjugated to tris(tert-butyl) ester–protected 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) chelators. We then deprotected the chelating carboxylate groups and purified the peptide conjugates. Radiolabeling was performed under standard conditions, was complete in 5 min, and gave high radiochemical yields without the need for high-performance liquid chromatography (HPLC) purification (fig. S2). Specific activities ranged from 324 to 462 GBq/μmol. We estimated type I collagen affinity by incubating increasing concentrations of nonradioactive Ga probes with either type I rat or type I human collagen (21). The dissociation constant (K_d) for Ga-CBP8 binding to type I human collagen was 2.1 ± 0.1 μM and 4.6 ± 0.5 μM for rat collagen, whereas the control compound Ga-CBP12 showed weaker binding to human collagen (K_d = 42 ± 5 μM) and rat (K_d = 50 ± 10 μM) collagens (figs. S3 and S4).

Mice were injected intravenously with about 3.7 MBq of either \(^{68}\)Ga-CBP8 or \(^{68}\)Ga-CBP12, and the change in the decay-corrected signal in the heart was measured by PET as a function of time. Both probes showed similar biexponential clearance, and we estimated similar blood half-lives from fits to the data (32.9 ± 4.5 min for \(^{68}\)Ga-CBP8 and 30.4 ± 3.0 min for \(^{68}\)Ga-CBP12; P = not significant, n = 5 for each probe). Urine was collected at 150 min after probe administration and injected onto an analytical HPLC column, and the results were compared with standards of pure probe. Both probes were >90% intact in urine, indicating that the probes are highly stable in vivo (fig. S5).

\(^{68}\)Ga-CBP8 specifically binds collagen in the bleomycin mouse model of pulmonary fibrosis

A single transtracheal instillation of bleomycin (BM) (2.5 U/kg) results in histopathology consistent with pulmonary fibrosis. Two weeks after instillation, all of the BM-injured mice had histopathological findings of substantial pulmonary fibrosis, including excessive interstitial deposition of collagen as demonstrated by Sirius Red staining, and destruction of lung architecture; sham animals, which received transtracheal saline, showed no signs of pulmonary disease (Fig. 1A). The BM-injured lungs exhibited a lymphoplasmacytic infiltrate along with excessive collagen deposition as visualized with Sirius Red in the areas of fibrosis, with a predominant subpleural and peribronchial distribution. Lungs from sham animals had preserved alveolar architecture, with no excess collagen deposition or alveolar infiltration.

As expected, disease progressed in a stepwise fashion as determined by histological Ashcroft scoring of lung fibrosis (28). Seven days after instillation of BM, most animals had moderate fibrous thickening of alveolar or bronchiolar walls without damage to lung architecture (Ashcroft score, 2.3 ± 0.3; range, 2 to 3) (Fig. 1B). Disease progressed with formation of fibrous bands, small fibrous masses, or large fibrous areas with definite damage to lung structure (Ashcroft score, 5.8 ± 0.4; range, 4 to 7 at day 14). The amount of lung tissue affected by the disease (measured with Sirius Red staining) also increased with time: 9% of the area of tissue sections from the right lung of BM-injured mice was affected by disease at day 7, whereas this increased to 28% at day 14 (Fig. 1C). Sham animals exhibited histologically normal lung tissue sections. Consistently, collagen deposition [as determined by analysis of hydroxyproline (29) content in the left lung] increased progressively with time (Fig. 1D).

To determine whether the \(^{68}\)Ga-CBP8 signal was an accurate reflection of disease progression, we compared mice injured with BM at days 7 and 14 after instillation. Ex vivo measurement of probe uptake into the lung increased with disease progression in the BM-injured mice [0.028 ± 0.005% injected dose per lung (% ID/lung) at day 7; 0.083 ± 0.008% ID/lung at day 14] (Fig. 1, E and F). Additionally, there was a strong correlation between probe uptake in the lung and lung hydroxyproline content (r^2 = 0.80, P < 0.0001) (Fig. 1G).

To demonstrate the specificity of \(^{68}\)Ga-CBP8, we compared its uptake into lung with that of the isomer \(^{68}\)Ga-CBP12, in which one of the cysteine amino acids was changed from L- to D-chirality (figs. S6 to S8). \(^{68}\)Ga-CBP8 accumulated specifically in fibrotic lungs of BM-treated mice but not in the healthy lungs of control mice, whereas \(^{68}\)Ga-CBP12 was not preferentially taken up into lungs of BM-treated mice compared to controls (Fig. 2A). There were no significant differences in hydroxyproline content between the BM-treated mice that received \(^{68}\)Ga-CBP8 and those that received \(^{68}\)Ga-CBP12 (Fig. 2B). The control probe \(^{68}\)Ga-CBP12 showed no preferential uptake in the lungs of BM-injured mice compared to control mice, as determined by ex vivo and PET data analysis (Fig. 2, C and D). The distribution of \(^{68}\)Ga-CBP12 in other organs was similar to that of \(^{68}\)Ga-CBP8 (Fig. 2E, figs. S6 to S8, and table S1). These results show the in vivo specificity of \(^{68}\)Ga-CBP8 for type I collagen, which allows the noninvasive detection and monitoring of progression of pulmonary fibrosis in the BM-treated mouse model.

\(^{68}\)Ga-CBP8 detects and stages disease in a mouse model of pulmonary fibrosis associated with enhanced vascular permeability

IPF is generally thought to result when a lung-injuring environmental stimulus is experienced by a person with a genetic predisposition to pulmonary fibrosis. In the context of such a genetic predisposition, fibrosis is thought to result from aberrant or exaggerated wound-healing responses to a relatively common and/or mild lung injury, which would be well tolerated and repaired without fibrosis by most people (30, 31). A growing number of mouse models are trying to capture this important “gene-by-environment” nature of pulmonary fibrogenesis (32). We used a low-dose BM vascular leak (LDBVL) model that combines the S1P receptor functional antagonist fingolimod (FTY720) to disrupt endothelial barrier function with low-dose BM to induce mild lung injury (33). Sustained exposure to FTY720 causes increased vascular leak and intra-alveolar coagulation after lung injury, which also leads to an exaggerated fibrotic response to a low dose of BM challenge (33).

One group of mice (LDBVL) was treated with a low dose of BM and the vascular leak agent FTY720 (n = 9). A second group (LDB) (n = 4) received a low dose of BM, and the third group (FTY) (n = 6) received the vascular leak agent only. FTY720 was administered intraperitoneally to the mice at 1 mg/kg three times a week (Fig. 3A). The three groups were imaged at day 14 after BM or vehicle instillation. After imaging, the mice were euthanized, and the right lung was taken for biochemical analysis. The LDBVL mice showed an average fibrosis score of 6 (±0.2; range,

Fig. 1. Probe $^{68}$Ga-CBP8 monitors disease progression in the BM mouse model of pulmonary fibrosis. (A) Representative images of lung tissue stained with hematoxylin and eosin (H&E) and Sirius Red (magnification, ×10; scale bar, 300 μm) for sham and BM-treated mice at days 7 and 14 after BM instillation; higher-magnification views are also displayed (×40; scale bar, 60 μm). (B to D) Disease progresses in a stepwise fashion as determined by histological Ashcroft scoring of lung fibrosis (B), by histological quantification of the area affected by disease (C), and by hydroxyproline analysis (D). (E) Ex vivo lung uptake of $^{68}$Ga-CBP8 increases with disease progression in the BM-treated mice: 5-fold higher in BM mice 14 days after instillation than in sham animals and 1.5-fold higher in BM mice 14 days after instillation than in BM mice 7 days after instillation. (F) Correlation of ex vivo $^{68}$Ga-CBP8 lung uptake and Ashcroft score. (G) Correlation between ex vivo lung uptake of $^{68}$Ga-CBP8 and lung hydroxyproline. Data were analyzed with one-way analysis of variance (ANOVA), followed by post hoc Tukey tests with two-tailed distribution. For (B) to (F), data are displayed as box plots, with the dark band inside the box representing the mean, the bottom and top of the box representing the first and third quartiles, and the whiskers representing the minimum and maximum values. For all of the experiments shown in this figure: n = 11 for sham, n = 4 for BM-treated mice at day 7, and n = 7 for BM-treated mice at day 14.

The LDB mice showed an average fibrosis score of 1.5 (±0.9; range, 0 to 7), whereas all FTY mice showed a score of 0 (Fig. 3B). Less than 1% of the total area of tissue sections from the right lung was affected by disease in LDB animals (measured by Sirius Red staining), whereas 18% of the total area was affected by disease in the LDBVL group (Fig. 3C). There was no area affected by disease in the right lungs of the FTY animals upon histological examination. Figure 3D shows twice as much hydroxyproline in the left lung of LDBVL animals compared with LDB and FTY mice (116.9 ± 4.9 μg for LDBVL, 59.1 ± 4.5 μg for LDB, and 49.2 ± 2.6 μg for FTY; P < 0.0001). There was no significant difference in hydroxyproline content in the left lung between LDB and FTY animals (P = 0.4057).

Consistently, PET quantification showed a significantly higher signal in lungs of LDBVL mice (0.98 ± 0.07% ID/cc) compared to lungs of FTY animals (0.30 ± 0.02% ID/cc; P < 0.0001) and LDB animals (0.33 ± 0.02% ID/cc; P < 0.0001) (Fig. 3E). There was no significant difference in lung signal measured by PET image analysis between the FTY and the LDB group (P = 0.9156). Ex vivo quantification of $^{68}$Ga-CBP8 uptake revealed five times more uptake in the LDBVL group than in the FTY group (P < 0.0001) and three times more in the LDBVL group compared to the LDB group (P < 0.0001) (Fig. 3F and fig. S9). The difference in lung uptake between the LDB and the FTY groups was not statistically significant (P = 0.8202). Hydroxyproline content was strongly correlated with % ID/cc ($r^2 = 0.86$, P < 0.0001) (Fig. 3G) and % ID/lung ($r^2 = 0.93$, P < 0.0001) (Fig. 3H). These results demonstrate the in vivo specificity of $^{68}$Ga-CBP8 for detection of excess collagen deposition in a second model of pulmonary fibrosis.

In a separate group of LDBVL mice, we performed a test-retest study (table S2). Reproducibility was evaluated in seven LDBVL mice by scanning each mouse twice, with an interval of 24 hours between scans, 13 days after BM instillation. Paired t tests revealed no statistically significant difference between the values of % ID/cc between test and retest for both lung and muscle regions of interest (P = 0.8262). Reproducibility was calculated by using the % ID/cc of the first scanning segment in lung or muscle, as 100 × [% ID/cc (test) - % ID/cc (retest)]/% ID/cc (test). Within-subject test-retest variability was <12% in the lungs and <7% in muscle. The intraclass correlation coefficient, which is a measure of the reproducibility of within-subject data relative to between-subject data, was 0.93 for lung analysis and 0.99 for muscle analysis (34). Reproducible measurements in mouse lungs are challenging to obtain because of the variation in lung density within individual mice. Breathing rate and position of the subject in the scanner are also factors influencing reproducible measurement in the lungs (35). Nevertheless, our test-retest experiment illustrates that quantitation of fibrosis with $^{68}$Ga-CBP8 can yield reproducible results.
68Ga-CBP8 PET allows monitoring of the response to antifibrotic therapy in mice

We monitored the antifibrotic effects of 3G9, a murine antibody targeted to integrin αvβ6, with 68Ga-CBP8 PET. The humanized version of 3G9, STX-100 (Biogen), has successfully completed phase 1 clinical testing and is now under investigation in a phase 2 clinical trial of IPF (ClinicalTrials.gov identifier: NCT01371305). Integrin αvβ6 is a key activator of transforming growth factor–β (TGF-β) signaling in the lung (12, 13), and specific targeting of αvβ6 with 3G9 can partially prevent pulmonary fibrosis in mice without systemic disruption of other homeostatic roles of TGF-β (36, 37).

Mice injured with a low dose of BM and the vascular leak agent were treated with the anti-αvβ6 antibody 3G9 (LDBVL + 3G9 group) or the irrelevant isotypic antibody 1E6 (LDBVL + 1E6 group) (37). Here, a control group of mice received the 3G9 antibody only (3G9 group). FTY720 was administered intraperitoneally to the mice at 1 mg/kg three times a week starting on day 0. PET-CT imaging, biodistribution, and hydroxyproline analysis were performed on LDBVL + 3G9, LDBVL + 1E6, and 3G9 mice 14 days after the initiation of administration of the different compounds (n = 11, 11, and 5, respectively), and data were compared to those for the LDBVL group (n = 9) shown in Fig. 3.

Treatment with the therapeutic antibody 3G9 reduced pulmonary fibrosis in the LDBVL group as assessed by histology (Fig. 4A) and by hydroxyproline quantification (Fig. 4C). LDBVL mice showed an average fibrosis score of 6 (±0.2; range, 4 to 7), whereas LDBVL + 3G9 mice had an average score of 4 (±0.3; range, 1 to 6), LDBVL + 1E6 mice showed an average fibrosis score of 6 (±0.3; range, 5 to 7), and mice treated with 3G alone had histologically normal lungs with a score of 0. Fourteen percent of the total area of right lung tissue sections was affected by disease in LDBVL mice, whereas only 7% was affected for the LDBVL + 3G9 group and 20% for LDBVL + 1E6 animals. There was no lung area affected by disease in 3G9-treated animals. Hydroxyproline analysis of the left lung showed significantly lower values in lungs of LDBVL + 3G9 mice compared to those of LDBVL and LDBVL + 1E6 mice (83.8 ± 2.7 μg per left lung for LDBVL + 3G9 mice, 116.5 ± 4.9 μg per left lung for LDBVL mice, and 108.9 ± 3.5 μg per left lung for LDBVL + 1E6 mice). There were no significant differences in hydroxyproline content between LDBVL + 3G9–treated and 3G9-treated mice or between LDBVL and LDBVL + 1E6 mice.

Similar effects of 3G9 treatment were also seen by lung PET imaging, where the lung PET signal was similar to what was seen in control mice and significantly lower than what was observed in the fibrotic group (Fig. 4B). Quantification of the 68Ga-CBP8 PET signal showed 1.5 times higher lung uptake in the LDBVL animals that received the irrelevant

---

**Fig. 2.** 68Ga-CBP8 is specifically taken up by fibrotic but not healthy lungs (BM model). (A) Representative fused PET-CT images show specific accumulation of 68Ga-CBP8 (left images) in fibrotic but not in control lungs; 68Ga-CBP12 (right images) showed no preferential uptake in the lungs of BM-treated mice compared to control mice. Grayscale image shows CT image, and color scale image shows PET image from integrated data 50 to 80 min after probe injection. (B) Hydroxyproline level was significantly higher in fibrotic BM-treated than in sham-treated animals. (C) PET activity values for 68Ga-CBP8 and 68Ga-CBP12 in sham- and BM-treated mice (50 to 80 min after injection). Data are expressed as percent injected dose per cubic centimeter of tissue (% ID/cc). Data show significantly higher uptake in fibrotic lungs with 68Ga-CBP8. (D) Ex vivo uptake of 68Ga-CBP8 and 68Ga-CBP12 in lungs from sham- and BM-treated mice 150 min after injection expressed as % ID/cc. (E) Distribution of 68Ga-CBP8 and 68Ga-CBP12, expressed as percent injected dose per gram of tissue (% ID/g) (mean ± SE) in various organs, was similar except in fibrotic lungs. Inset) Same data as in (E) expressed as % ID/lung. Data were analyzed using one-way ANOVA, followed by post hoc Tukey tests with two-tailed distribution. For all of the experiments shown in this figure: n = 4 for sham injected with 68Ga-CBP8, n = 4 for BM-treated mice injected with 68Ga-CBP12, n = 11 for sham injected with 68Ga-CBP8, and n = 7 for BM-treated mice injected with 68Ga-CBP8. Data were analyzed using one-way ANOVA, followed by post hoc Tukey tests with two-tailed distribution. For all of the experiments shown in this figure: n = 4 for sham injected with 68Ga-CBP8, n = 4 for BM-treated mice injected with 68Ga-CBP12, n = 11 for sham injected with 68Ga-CBP8, and n = 7 for BM-treated mice injected with 68Ga-CBP8. For (B) to (D), data are displayed as box plots, with the dark band inside the box representing the mean, the bottom and top of the box representing the first and third quartiles, and the whiskers representing the minimum and maximum values.
antibody (fibrotic mice; LDBVL + 1E6, 1.00 ± 0.08% ID/cc) than in mice of the LDBVL group treated with the anti-α,β6 antibody (LDBVL + 3G9, 0.63 ± 0.06% ID/cc; P = 0.0017) (Fig. 4D). Organ uptake measured by ex vivo analysis was not significantly different among groups, except for the lungs where there was three times more uptake in the LDBVL + 1E6 group than in the LDBVL + 3G9 group (P = 0.0004) and six times higher uptake in the LDBVL + 1E6 group than in the 3G9-treated group (P < 0.0001) (Fig. 4E and fig. S10). Lung uptake of 68Ga-CBP8 was not statistically different between the LDBVL + 3G9 group and the 3G9-treated group (P = 0.4524). These results illustrate that 68Ga-CBP8 enables noninvasive monitoring of in vivo responses to therapeutic interventions in animals affected by pulmonary fibrosis.

**Probe 68Ga-CBP8 allows monitoring of collagen content in human IPF lung samples**

To determine whether our findings could be translated to human tissues, we evaluated the binding of the probe 68Ga-CBP8 to fresh human lung tissues from three IPF patients undergoing pneumonectomy before lung transplantation (figs. S11 to S13). Lung tissues were collected fresh within 1 hour of resection. Three sampling areas were defined in the lung of the patient [the superior upper lobe (S1), the lateral upper lobe (S2), and the lower lobe (S3)], and chunks of tissues were sampled in these three areas. We incubated samples from S1, S2, and S3 (70 to 100 mg) with 68Ga-CBP8 for 2 hours (n = 5 per area) and quantified the probe uptake. Once 68Ga-CBP8 radioactivity had decayed, we incubated the samples with 68Ga-CBP12 for 2 hours and quantified 68Ga-CBP12 uptake. The uptake of 68Ga-CBP8 in human lung samples showed differences in collagen concentration among lobes in the three IPF patients and heterogeneity of disease progression among patients (Fig. 5A). 68Ga-CBP12 uptake was significantly lower than 68Ga-CBP8 uptake in all samples. We performed histological analyses on samples just adjacent to those used for probe incubation (Fig. 5B). Uptake of 68Ga-CBP8 in IPF human lung tissue samples increased linearly with increasing fibrosis, as measured by Sirius Red quantification of the area affected by disease (r² = 0.94, P < 0.0001) (Fig. 5C). The 68Ga-CBP12 signal did not change with collagen concentration in IPF human tissue samples, demonstrating the specificity of 68Ga-CBP8 for collagen.

**DISCUSSION**

Fibrosis, regardless of its cause or location, is characterized by excess deposition of collagens, primarily type I collagen, and other extracellular matrix proteins in the parenchyma (20). Histological proof of fibrosis is predicated on collagen staining. Here, we developed a method for direct molecular PET imaging of type I collagen as a noninvasive means of detecting and monitoring pulmonary fibrosis. The major advantages of PET are that it enables in vivo visualization of molecular physiological processes in real time while at the same time allowing quantification by measuring regional concentration of the radiation source. The mass dose of 68Ga-CBP8 that would be required for administration is extremely low (<100 μg per human subject) and, like most PET probes, is very safe because of the ultralow concentration of the radiation source. The mass dose of 68Ga-CBP8 that would be required for administration is extremely low (<100 μg per human subject) and, like most PET probes, is very safe because of the ultralow concentration of the radiation source. The mass dose of 68Ga-CBP8 that would be required for administration is extremely low (<100 μg per human subject) and, like most PET probes, is very safe because of the ultralow concentration of the radiation source.

To generate our probe, we modified a known collagen-specific peptide with a chelator so that it binds the 68Ga ion. Gallium-68 is a positron-emitting radioisotope that is produced from a 68Ge/68Ga generator system, and therefore 68Ga radiopharmacy does not require an on-site cyclotron, similar to 99Mo/99mTc-based radiopharmacy. The chelation reaction to introduce 68Ga is quantitative, driven by the high thermodynamic stability of the resultant 68Ga complex. The 68-min half-life of 68Ga permits facile production of the probe, and the short half-life results in low radiation exposure to the subject. The radiochemistry is amenable to kit formulation and/or automation, with a low barrier to clinical translation. There has been a tremendous increase in the number of clinical studies with 68Ga probes over the past year around the world, including within the United States (38).

We demonstrated that PET imaging with our collagen-targeted probe, 68Ga-CBP8, is sensitive enough to detect pulmonary fibrosis in the commonly used BM mouse model. Our study showed that...
stage pulmonary fibrosis. The control probe, 68Ga-CBP12, showed similar low uptake in the lungs of both fibrotic and control mice, dem-

68Ga-CBP8 was a result of specific collagen binding.

We further validated the probe in a second model of pulmonary fibrosis with mice in which a host response to injury was exaggerated by increasing the animals’ vascular permeability. Here, a low-dose BM challenge plus a vascular leak–inducing agent produces robust fibrosis, whereas the low-dose BM challenge alone causes only a mild, self-limited injury in control mice (33, 40). This model captures an important aspect of IPF pathogenesis, in which fibrosis is thought to result from an aberrant or exaggerated host responses to relatively common and/or mild environmental injuries, which may be well tolerated and repaired in most people. Here, PET imaging of collagen with 68Ga-CBP8 successfully identified animals with pulmonary fibrosis and, additionally, detected blunted disease progression in animals treated with 3G9, a murine antibody targeted to integrin α,β6, that interferes with TGF-β activation, leading to reduced TGF-β signaling.

Our data raise the possibility that 68Ga-CBP8 more readily/avidly binds newly formed collagen in active disease than it does in established, mature collagen. For instance, we see relatively low uptake of 68Ga-CBP8 in bone or skin, which are rich in type I collagen. The lungs themselves are rich in collagen, and by direct biochemical measurement, lung collagen increases two- to threefold in mouse models of pulmonary fibrosis. We nevertheless see a sixfold higher probe uptake in fibrotic mouse lungs compared to control lungs, suggestive of higher binding to the collagen newly formed during fibrosis. Similar observations were made in other models of fibrosis with an analogous MRI probe (21–26).

There are two factors that could contribute to the specificity of the probe for newly formed collagen and active fibrosis.

The first relates to the structural nature of type I collagen. A single collagen molecule (tropocollagen) is made of three polypeptide strands that assemble into a microfibril triple helix. In normal tissue, these microfibrils interdigitate, are cross-linked, and form stable fibrils (41). Therefore, most of the collagen monomers within these fibrils are inaccessible to a molecular probe like 68Ga-CBP8 because most monomers will be inside the fibril and the probe can only access the fibril surface. However, in active fibrosis, collagen production is up-regulated, and new collagen is not yet fully organized into stable fibrils. As a result, collagen monomers are more accessible to the probe. If confirmed, this property may augment the ability of 68Ga-CBP8 to provide

- **Fig. 4.** 68Ga-CBP8 PET allows monitoring of the response to antifibrotic therapy in mice. (A) Representative images of lung tissue stained with H&E and Sirius Red (magnification, ×10; scale bar, 300 μm) for mice treated with 3G9 only (n = 5), for mice treated with a low dose of BM and FTY720 (LDBVL n = 9), for LDBVL mice receiving 3G9 (LDBVL + 3G9; n = 11), and for LDBVL mice receiving 1E6 (LDBVL + 1E6; n = 11); higher-magnification views are also displayed (×40; scale bar, 60 μm). Representative fused PET-CT images show specific accumulation of 68Ga-CBP8 in the lungs of mice from the LDBVL and LDBVL + 1E6 groups but low PET signal in the lungs of the control 3G9 or treated LDBVL + 3G9 groups. Grayscale image shows CT image, and color scale image shows PET image from integrated data 50 to 80 min after probe injection. (C) Hydroxyproline content was significantly higher in animals from the LDBVL and LDBVL + 1E6 groups than in those from the 3G9 group (P = 0.0007) and control 3G9 or treated LDBVL + 3G9 groups. Grayscale image shows CT image, and color scale image shows PET image from integrated data 50 to 80 min after probe injection. (C) Hydroxyproline content was significantly higher in animals from the LDBVL and LDBVL + 1E6 groups than in those from the 3G9 group (P = 0.0007) and control 3G9 or treated LDBVL + 3G9 groups. (D and E) Similar effects were seen for quantitative PET data (D) and ex vivo uptake in the lungs. Data were analyzed using one-way ANOVA, followed by post hoc Tukey tests with two-tailed distribution. For (C) to (E), data are displayed as box plots, with the dark band inside the box representing the mean, the bottom and top of the box representing the first and third quartiles, and the whiskers representing the minimum and maximum values. For all of the experiments shown in this figure, n = 5 for the 3G9 group, n = 9 for the LDBVL group, n = 11 for the LDBVL + 3G9 group, and n = 11 for the LDBVL + 1E6 group.
a much-needed assessment of “disease activity” in IPF and other fibrotic diseases.

Whereas HRCT can accurately measure an IPF patient’s disease severity at the time of evaluation, this imaging modality and other currently available measures to monitor IPF patients provide little information about disease activity (that is, how likely that patient’s fibrosis is to worsen in the upcoming weeks and months). If the ability of 68Ga-CBP8 molecular imaging to assess disease activity in pulmonary fibrosis patients is validated, it could improve patient care and clinical research in IPF in several important ways. Progress in IPF patient care and clinical research has been hampered by the substantial heterogeneity of the disease. Although IPF has a very poor prognosis overall, its clinical course in different patients is highly variable (3). Whereas some patients have active disease that quickly progresses to respiratory failure, others have minimally active disease that remains clinically stable for long periods of time (3). The ability to distinguish IPF patients who are worsening rapidly from those who are remaining stable would enable clinicians to individualize patient care plans. Being able to make this distinction would also allow clinical trials of new IPF therapies to enroll subjects more likely to progress during the period of observation, improving the ability of these trials to detect treatment effects. Additionally, because current assessments of IPF usually take 6 or 12 months to show meaningful changes, being able to assess disease activity would enable faster assessments of patient responses to new therapies.

68Ga-CBP8 has moderate affinity for collagen (2.1 μM), which may also result in better sensitivity to fibrosis. For instance, we measured 50 μg of hydroxyproline in the left lung of control mice. Assuming that all the hydroxyproline arises from collagen and that it comprises ~13% of collagen, this results in a collagen monomer concentration of ~10 μM, which rises in excess of 25 μM in fibrotic lungs. Thus, in normal lung, the collagen concentration is at or below (depending on accessibility to the collagen) the K_d of the probe, which results in poor uptake. However, in fibrosis, the target concentration is in excess of the K_d, resulting in increased probe uptake and the observed collagen concentration–dependent uptake of the probe. The results of our study suggest that 68Ga-CBP8 PET may be a useful complement to HRCT for noninvasive characterization of pulmonary fibrosis.

HRCT provides a good measure of fibrotic burden, whereas 68Ga-CBP8 might highlight regions where fibrosis is more active.

An important limitation of the current study is that BM fibrosis in the animal lacks important features of the human disease. The slow and irreversible progression of fibrosis seen in IPF patients is not reproduced in the BM model. Chronic diseases are notoriously difficult to model. IPF is particularly complicated because the etiology and natural history of the disease is unclear, and no single trigger is known that is able to induce “IPF” in animal models.

To assess probe performance in human tissues, we incubated human IPF lung tissue samples with 68Ga-CBP8 and were able to correlate probe uptake with histological findings of IPF in these samples. 68Ga-CBP12 was not sensitive to collagen changes in IPF human tissue samples, which demonstrates the specificity of 68Ga-CBP8 for collagen. Although this pilot study was limited to three patients, the data provide proof-of-principle evidence of the potential of 68Ga-CBP8 PET as an imaging agent for pulmonary fibrosis in humans. The human tissue data support the hypothesis that the probe is more sensitive to newer, less organized collagen. We found that uptake in a region of the lung that was characteristic of dense, established subpleural fibrosis with microscopic honeycomb change was higher than in a region reflective of end-stage fibroelastosis with cystic honeycomb change. This distinction suggested that as fibrosis becomes end stage, a larger fraction of the matrix is elastin and the collagen is more organized and less available for binding to our probe. The barrier to translate our collagen-binding PET probe into clinic is very low. Unlike other imaging modalities (for example, MRI and optical), the low mass dose required for PET allows clinical translation under the U.S. Food and Drug Administration (FDA)
exploratory investigational new drug mechanism on the basis of a single high-dose acute toxicity study in rodents.

Recently, the FDA approved two different therapeutic agents for the treatment of IPF in the United States, pirfenidone and nintedanib, largely based on results from the CAPACITY (42), ASCEND (43), and INPULSIS trials (44). Both drugs slow functional decline and disease progression and reduce long-term mortality in patients with mild to moderate IPF, highlighting the importance of early diagnosis and initiation of treatment. The usefulness of these drugs in other forms of pulmonary fibrosis is starting to be evaluated, including scleroderma-associated interstitial lung disease, chronic hypersensitivity pneumonitis, and radiation pneumonitis. If current antifibrotic therapy can slow functional decline and disease progression in fibrotic lung diseases, then early detection of pulmonary fibrosis of any cause and initiation of treatment could benefit patients across this broad category of lung diseases. Because lung architectural distortion may be absent early in the course of fibrotic lung diseases, HRCT often cannot distinguish fibrosis from other pathological processes in the lung. In this regard, our results may represent a consistent and reliable noninvasive method to detect excess collagen deposition in the lungs, even early in the course of pulmonary fibrosis. This ability of 68Ga-CBP8 molecular imaging, as well as the potential application to assess the rate of progression, or disease activity of pulmonary fibrosis, suggests that translation of this approach to human will benefit patients with IPF and other fibrotic lung diseases.

**MATERIALS AND METHODS**

**Study design**

The objectives of this study were to address the clinically unmet need of noninvasive tools to diagnose IPF at early stage, to quantify and stage fibrosis, and to monitor disease progression. These goals were addressed by (i) evaluating the efficacy and specificity of the probe to detect and stage disease in an established animal model for pulmonary fibrosis (BM), (ii) evaluating the probe efficacy to detect disease and its capacity to monitor treatment response in a second model of pulmonary fibrosis using mice in which a host response to injury has been exaggerated by increased vascular permeability, (iii) and initiating a pilot study to translate these findings using human IPF tissue samples.

All experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines (45), and were approved by the institution’s animal care and use committee. Evaluation of 68Ga-CBP8 and 68Ga-CBP12 uptake measurements in animals was performed in a nonblinded fashion. Authors were blinded for histology analysis. Because 68Ga-CBP8 microPET imaging is a new imaging technology, it is difficult to estimate sample size with adequate power. An n = 4 to 13 was selected for these well-controlled models with a low (<10%) error in consecutive studies (table S2). Binding studies were conducted using three independent experiments. No samples or animals were excluded from data analyses.

Fresh lung tissue samples were collected from explanted IPF lungs obtained from three IPF patients undergoing transplantation. The Partners Human Research Committee Institutional Review Board approved this study. Informed consent was obtained from the patients.

**Synthesis of precursors and nonradioactive standards**

All chemicals were purchased commercially and used without further purification. The cyclic disulfide peptide precursors of CBP8 and CBP12 [cPep(8) and cPep(12)] were custom-made by American Peptide. The tri-tert-butyl-protected activated ester NODAGA-N-hydroxysuccinimide ([1(Bu)₃N]NODAGA-NHS] was synthesized in-house following a published procedure (46) starting from 1,4,7-triazacyclononane (CheMatech). ([1(Bu)₃N]NODAGA-cPep(x)).

Three equivalents of ([1(Bu)₃N]NODAGA-NHS were added to solution of cPep(x) (x = 8, 12) in 1 ml of dimethylformamide. The pH of each solution was adjusted to 6.5 using diisopropylethylamine, and the mixtures were stirred at room temperature for 24 hours. ([1(Bu)₃N]NODAGA-cPep(8)) and ([1(Bu)₃N]NODAGA-cPep(12)) were purified separately by reversed-phase semipreparative purification [Dynamax HPLC system, Phenomenex Luna C18 column (5 μm; 250 mm × 21.2 mm), water/acetonitrile gradient (85:15; 60:40 in 30 min) containing 0.1% (v/v) trifluoroacetic acid (TFA); the absorbance at 280 nm was monitored for detection]. The two products had a purity of >98%, as determined by liquid chromatography–mass spectrometry (LC-MS) [Agilent 1100 Series apparatus with an LC/MSD trap and Daly conversion detector with ultraviolet (UV) detection at 220, 254, and 280 nm; Phenomenex Kinetex C18 column (2.6 μm; 100 mm × 4.6 mm); water/acetonitrile gradient (95:5; 5:95 in 10 min) containing 0.1% (v/v) formic acid, ([1(Bu)₃N]NODAGA-cPep(8)): molecular weight for C₁₉₁H₂₈₅N₃₇O₄₃S₂. MS(ESI) calculation: 970.0 [(M + 4H)/4]⁴⁺; found: 969.5. ([1(Bu)₃N]NODAGA-cPep(12)): molecular weight for C₂₄₆H₄₃₅N₃₇O₄₃S₂. MS(ESI) calculation: 970.0 [(M + 4H)/4]⁴⁺; found: 969.7.

**NODAGA-cPep(x).**

In two separate reaction vessels, about 20 mg of ([1(Bu)₃N]NODAGA-cPep (x) (x = 8, 12) was dissolved in a 1-ml solution of TFA, methanesulfonic acid, 1-dodecanethiol, and H₂O (92:3:2:2). Each reaction mixture was stirred for 2 hours. Cold diethyl ether was added to precipitate out the solids. The mixtures were centrifuged, and the supernatant was removed. The solids were washed with diethyl ether and dried to give the product as white solids. NODAGA-cPep(8) and NODAGA-cPep(12) were purified by reversed-phase semipreparative purification. The two products had a purity of >98%, as determined by LC-MS. NODAGA-cPep(8): molecular weight for C₁₅₇H₂₁₃N₃₇O₄₃S₂. MS(ESI) calculation: 843.8 [(M + 4H)/4]⁴⁺; found: 843.4. NODAGA-cPep(12): molecular weight for C₂₀₅H₂₆₅N₃₇O₄₃S₂. MS(ESI) calculation: 843.8 [(M + 4H)/4]⁴⁺; found: 843.5.

**69/71Ga-NODAGA-cPep(8).**

Three milligrams of NODAGA-cPep(8) were dissolved in 2 ml of sodium acetate buffer (20 mM, pH 4.1). A sample of 296 μl of a 3 mM 69/71Ga(NO₃)₃ was added in the vessel, and the reaction mixture was stirred at 60°C for 20 min. 69/71Ga-NODAGA-cPep(8) was purified by reversed-phase semipreparative HPLC. The product had a purity of >98%, as determined by LC-MS. Molecular weight for C₁₅₇H₂₁₀Ga₃N₃₇O₄₃S₂. MS(ESI) calculation: 860.3 [(M + 4H)/4]⁴⁺; found: 860.5.

**69/71Ga-NODAGA-cPep(12).**

Five milligrams of NODAGA-cPep(12) were dissolved in 2 ml of sodium acetate buffer (20 mM, pH 4.1). A sample of 1.5 ml of a 3 mM 69/71Ga(NO₃)₃ was added in the vessel, and the reaction mixture was stirred at 60°C for 20 min. 69/71Ga-NODAGA-cPep(12) was purified by reversed-phase semipreparative HPLC. The product had a purity of >98%, as determined by LC-MS. Molecular weight for C₁₅₇H₂₁₀Ga₃N₃₇O₄₃S₂. MS(ESI) calculation: 860.3 [(M + 4H)/4]⁴⁺; found: 860.5.

**Radiosynthesis**

68GaCl₃ was obtained from a SnO₂-based 68Ge/68Ga generator (iThemba LABS). 68GaCl₃ [10 mCi, in 0.5 ml of HCl (0.6 M)] was...
diluted with 200 μl of pH 5 sodium acetate (3 M) to reach pH 4.1. A sample of 180 μl of the 68GaCl3 solution was combined to 5 μl of a 0.1 mM (NODAGA)-cPep(8) or (NODAGA)-cPep(12) solution [in sodium acetate (pH 4.1)], and the reaction mixture was heated at 60°C for 5 min and purified by Sep-Pak C18 cartridge (Waters) to remove any radiometal impurities (germanium-68 breakthrough). The radiochemical purity of the final solution of CBP8 and CBP12 was ≥99%, as determined by radio-HPLC analysis [Agilent 1100 Series HPLC unit with a Carroll/Ramsey radiation detector with a silicon PIN photodiode and with UV detection at 254 nm, Phenomenex Luna C18 column (2.6 μm; 100 mm × 46 mm), water/acetonitrile gradient (95:5, 5:95 in 10 min) containing 0.1% (v/v) TFA]. Specific activities ranged from 324 to 462 GBq/μmol.

Collagen binding
Binding isotherms were obtained using the cold version of the probes (69/71Ga-CBP8 or 69/71Ga-CBP12) by following a method previously reported (21).

Animal model and probe administration
In the standard-dose BM model (47), pulmonary fibrosis was induced in 10-week-old male C57/BL6 mice (20 to 28 g; Charles River Laboratories) by transtracheal administration of BM (2.5 U/kg) in 50 μl of phosphate-buffered saline (PBS) under direct vision using a small cervical incision. In the low-dose BM model associated with a vascular leak model (56), pulmonary fibrosis was induced in 8-week-old male C57/BL6 mice (22 to 28 g; Charles River Laboratories), were administered a single intratracheal dose of BM at 0.1 U/kg (low dose), in a total volume of 50 μl of sterile saline. FTY720 was administered intraperitoneally to the mice at 1 mg/kg dose of BM at 0.1 U/kg (low dose), in a total volume of 50 μl of sterile saline. FTY720 was administered intraperitoneally to the mice at 1 mg/kg three times a week. To effect treatment in the low-dose BM, vascular leak model, the therapeutic murine antibody 3G9 (anti-αvβ6-blocking antibody) and I6f (matched isotype control antibody) were used (48). All administrations of FTY720 and antibodies were initiated on day 0, ~30 min before BM challenge, and continued throughout the duration of the experiments.

Small-animal PET-CT imaging and analysis
Animals were placed in a small-animal PET/SPECT/CT scanner (Triumph, TriFoil Imaging), equipped with inhalation anesthesia and heating pad. Each animal was anesthetized with isoflurane (4% for induction, 1 to 1.5% for maintenance in medical air). After placement of an in-dwelling catheter in the femoral vein for probe administration, mice were positioned in the PET-CT and probe was given as a bolus. Dynamic imaging was performed for 120 min for sham and BM mice (day 7), FTY alone, LDB, LDBVL, and the organs were taken for biodistribution analysis. Instrument calibration was performed with phantoms containing small known amounts of radioactivity. Isotopic (0.3-mm) CT images were acquired over 6 min with 512 projections with three frames per projection (exposure time per frame, ~200 ms; peak tube voltage, 70 kV; tube current, 177 mA). PET and CT images were reconstructed using the LabPET software (TriFoil Imaging), and the CT data were used to provide attenuation correction for the PET reconstructions. The PET data were reconstructed using a maximum-likelihood expectation-maximization algorithm run over 30 iterations to a voxel size of 0.5 × 0.5 × 0.6 mm3. For the pharmacokinetic analyses, the PET data were reconstructed in 1-min (first 10 frames), 3-min (next 10 frames), and 10-min (last 8 frames) intervals out to 120 min after injection. Reconstructed PET-CT data were quantitatively evaluated using AMIDE software package (49). For each PET scan, volumes of interest (VOIs) were drawn over major organs on decay-corrected whole-body coronal images. The radioactivity concentration within organs was obtained from mean pixel values within the VOI and converted to counts per milliliter per minute and then divided by the injected dose (ID) to obtain an imaging VOI-derived percentage of the injected radioactive dose per cubic centimeter of tissue (% ID/cc). Size of the VOI was about 65 mm3 for the lungs, 53 mm3 for the heart, and 20 mm3 for the muscle.

Biodistribution protocol
The left lung, blood, urine, heart, liver, left rectus femoris muscle, spleen, small intestine, kidneys, and left femur bone were collected from all animals. The tissues were weighed, and radioactivity in each tissue was measured on a gamma counter (Wizard2 Auto Gamma, PerkinElmer). Tracer distribution was presented as % ID/gram for all organs. The radioactivity in the lung was reported as % ID/lung.

Human lung tissues were collected within 1 hour of resection. Samples were weighed (70 to 100 mg per sample), cut in small pieces, and introduced in an Eppendorf tube containing a solution of 68Ga-CBP8 (50 to 75 kBq) in PBS (1 ml). The mixture was shaken for 2 hours at room temperature. After centrifugation, supernatant (sup-1) was removed and kept for further analysis, and tissue samples were washed with 1 ml of PBS; this procedure was repeated twice for each sample. Wash solutions (wash-1 and wash-2) were kept for further analysis. Activities in tissue samples and in solutions sol-1, wash-1, and wash-2 were measured on a gamma counter. Activity in the tissue was presented as % lung uptake, defined by activity in the tissue measured by gamma counter divided by total activity (from tissue, sup-1, wash-1, and wash-2).

Ex vivo analysis
Mouse lung tissues (right lungs) were inflated and fixed with 10% formalin, embedded in paraffin, and cut into 5-μm sections. Tissue sections were stained with H&E and Picrosirius Red with a counterstain of Fast Green (Fig. 4A). Images were acquired using a Nikon TE2000 microscope (×10 and ×40 magnification). Sirius Red–stained sections were analyzed by a pathologist, who was blinded to the study, to score the amount of lung disease according to the method of Ashcroft et al. (28). In addition, % Sirius Red was quantified from the histology images using ImageJ as per our standard procedures (26). Human lung tissues were obtained just adjacent to fresh tissues for probe incubation and were fixed in 10% formalin, embedded in paraffin, and cut into 5-μm sections. Tissue sections were stained with H&E, Picrosirius Red, Masson trichrome, and Verhoeff’s elastic stain. Slides were scanned using a digital slide scanner (Aperio CS2, Leica Biosystems).

Quantification of collagen
Hydroxyproline in tissue was quantified by HPLC analysis of tissue acid digests, as previously described. Hydroxyproline is expressed as amount per lung (50).

Statistics
Unless otherwise noted, the results are expressed as means ± SEM (with n = 4 to 13 mice per group). Statistical analyses were performed...
with GraphPad Prism 7 software. A one-way ANOVA, followed by post hoc Tukey tests with two-tailed distribution, was used for analyzing the data between different groups. A P value of <0.05 was considered significant.

SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/9/384/eaaf4696/DC1

REFERENCES AND NOTES

Acknowledgments: We thank O. M. Ebubuomwan and J. Hooker for use of the 68Ge/68Ga generator; H. Chen, P. Vaghorn, D. Santos Ferreira, and H. Dibabalam for assistance during animal setup; S. E. Conley for scanning slides of human lung tissues; M. K. Selig for performing the electron microscopy imaging; and the Wellman Center for Photomedicine Pathophatology core for the work on the human lung tissues. Funding: This study was supported by the National Heart and Lung Blood Institute (R01HL116315). P.D. was supported by the Harvard/Massachusetts General Hospital (MGH) Nuclear Medicine Training program, which is funded by the U.S. Department of Energy (DE-SC0008430). We acknowledge instrumentation support from the National Center for Research Resources (microPET/SPECT/CT system; RR029495) and the Office of Director of Science and Technology (ODST) (DD1014650). Author contributions: P.C. initially conceptualized this project and supervised the entire project. P.D., L.F.T., N.J.R., T.A.R., P.W. provided the antibodies. M.M.-K., B.C.F., and L.P.H. analyzed histological data. P.D. developed the synthesis and synthesized the radioactive probes. P.D., L.F.T., N.J.R., T.A.R., C.K.P., F.B., and H.D. performed the animal experiments. P.D., L.F.T., B.C.F., and N.J.R. analyzed the data. P.W. provided the antibodies. M.M.-K., B.C.F., and L.P.H. analyzed histological data. L.P.H. enabled the human tissue samples. P.W. wrote the manuscript draft, which was then further refined by P.C. All other authors reviewed and edited the intermediate and final versions of the manuscript. Competing interests: P.C. has equity in Collagen Medical, the company that holds the patent rights to the peptides used in these probes. P.C. and B.C.F. are paid consultants to Collagen Medical. S.M.V. and P.W. are employees of Biogen. P.C. and P.D. are inventors on patent/patent application (WO 2015196208) submitted by MGH that covers the 68Ga-CBP8 probe. S.M.V. and P.W. are inventors on patent/patent application (US 7,465,449) submitted by Biogen and the University of California, San Francisco, that covers anti-uPA antibody 3G0. Data and materials availability: The patent on the 68Ga-CBP8 probe does not restrict the research or noncommercial use of the probe technique. The 68Ga-CBP8 probe can be obtained using the synthetic procedures described in the paper. Anti-uPA antibodies were provided by Biogen to the investigators at MGH under a material transfer agreement. These antibodies are available to other researchers under a material transfer agreement with Biogen.

Submitted 12 February 2016
Resubmitted 20 October 2016
Accepted 16 March 2017
Published 5 April 2017
10.1126/scitranslmed.aaf4696

Citation: P. Désogère et al., Sci. Transl. Med. 9, eaaf4696 (2017) 5 April 2017

11 of 11
Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models


Sci Transl Med 9, eaaf4696.
DOI: 10.1126/scitranslmed.aaf4696

Focusing on fibrosis
Although fibrosis is known to play a role in the progression of multiple diseases, affecting heart, lung, liver, and skin, among other organs, it remains difficult to visualize and diagnose noninvasively. To address this, Désogère and colleagues developed an imaging probe for positron emission tomography that detects type I collagen, an extracellular matrix protein present in fibrotic tissues. The probe detected fibrotic lung tissue in two mouse models of bleomycin-induced pulmonary fibrosis and in samples of human lungs from patients with idiopathic pulmonary fibrosis, where higher probe uptake correlated with regions of increasing fibrosis.

ARTICLE TOOLS
http://stm.sciencemag.org/content/9/384/eaaf4696

SUPPLEMENTARY MATERIALS
http://stm.sciencemag.org/content/suppl/2017/04/03/9.384.eaaf4696.DC1

RELATED CONTENT
http://stm.sciencemag.org/content/scitransmed/8/337/337ra65.full
http://stm.sciencemag.org/content/scitransmed/3/87/87ra53.full
http://stm.sciencemag.org/content/scitransmed/8/359/359ra131.full
http://stm.sciencemag.org/content/scitransmed/7/288/288ra79.full
http://stm.sciencemag.org/content/scitransmed/9/396/eaaf3694.full
http://stm.sciencemag.org/content/scitransmed/10/426/eaan5174.full
http://stm.sciencemag.org/content/scitransmed/10/429/eaan0333.full
http://stm.sciencemag.org/content/scitransmed/11/486/eaaf4865.full
http://stm.sciencemag.org/content/scitransmed/11/511/eaaw1237.full

REFERENCES
This article cites 50 articles, 12 of which you can access for free
http://stm.sciencemag.org/content/9/384/eaaf4696#BIBL

PERMISSIONS
http://www.sciencemag.org/help/reprints-and-permissions

Use of this article is subject to the Terms of Service

Science Translational Medicine (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title Science Translational Medicine is a registered trademark of AAAS.

Copyright © 2017, American Association for the Advancement of Science